抗肿瘤药物脂质体体内分析方法的研究进展  

Research Progress of Analysis Methods in vivo for Anti-tumor Drug Liposomes

作　　者：张琦 孙亚棋 高敬林 聂旭阳 冯章英[1] 王明霞[1] ZHANG Qi;SUN Yaqi;GAO Jinglin;NIE Xuyang;FENG Zhangying;WANG Mingxia(Department of Clinical Pharmacology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第四医院临床药理研究部,石家庄050000

出　　处：《中国药学杂志》2024年第1期1-6,共6页Chinese Pharmaceutical Journal

基　　金：科技部“十三五”新药创制重大专项项目资助(2020ZX09201006-003);河北省自然基金重点项目资助(H2021206432);河北省医学科学研究重点课题计划项目资助(20200105);。

摘　　要：抗肿瘤药物毒性大,不良反应多,而脂质体剂型能够降低药物毒性,减少药物活性降解,是一种有前景的靶向载体。目前大多数抗肿瘤药物脂质体的药动学研究主要以总浓度为指标,但游离药物才是其体内真正发挥药理作用的部分,因此游离药物的分离和测定显得十分重要。其中样品前处理是脂质体给药后游离药物分离和提取的关键一步。笔者从抗肿瘤药物脂质体的常用检测方法、前处理方法及体内药物分析实例等多个方面进行探讨,以期为脂质体类药物体内分析方法的建立提供参考。Anti-tumor drugs have high toxicity and adverse reactions.Liposome formulation can reduce drug toxicity and degradation of drug activity,which is a promising target vector.At present,the pharmacokinetic study of most anti-tumor drug liposomes mainly takes the total concentration as the index,but the free drugs are the part that really plays the pharmacological effect in vivo.So the separation and determination of the free drugs are very important.Sample pretreatment is a key step in the separation and extraction of free drugs after liposome administration.This article focuses on common detection methods,pretreatment methods and analysis examples,to provide reference for the establishment of analysis methods in vivo for anti-tumor drug liposomes.

关 键 词：抗肿瘤药物 脂质体 体内分析 样品前处理 游离浓度 

分 类 号：R944[医药卫生—药剂学] R917[医药卫生—药学]